arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Werewolf Therapeutics, Inc.

HOWL
$0.40 0.00 (-1.14%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Werewolf Therapeutics, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $19.4M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 34.7%
FCF / Share $0.14
Trailing P/E 5.0x
Price / Book 1.2x
FCF Yield 34.1%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-13.53M
↑ +25.2%
FCF / Share Free cash flow per share
$0.14
↑ +162.6%
Long-Term Debt Long-term obligations
$32.09M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Financial Health
25
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 27 quarters